Phase I IgG1 antibody treatment could halt fibrosis
Drug Discovery World
AUGUST 8, 2024
The first cohort of participants has been dosed in a Phase I trial MTX-474, a human IgG1 antibody designed to neutralise EphrinB2 signalling to treat fibrosis. WISP1 is a secreted matricellular protein shown to have a relevant role in fibrosis progression, measurable in human blood, and correlates with disease severity.
Let's personalize your content